Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

  title={Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.},
  author={Matthew N. Meriggioli and Donald Sanders},
  journal={The Lancet. Neurology},
  volume={8 5},
Acquired myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction in which patients experience fluctuating skeletal muscle weakness that often affects selected muscle groups preferentially. The target of the autoimmune attack in most cases is the skeletal muscle acetylcholine receptor (AChR), but in others, non-AChR components of the neuromuscular junction, such as the muscle-specific receptor tyrosine kinase, are targeted. The pathophysiological result is muscle endplate… CONTINUE READING
Highly Influential
This paper has highly influenced 33 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 231 extracted citations


Publications referenced by this paper.
Showing 1-10 of 176 references

Myasthenic disorders and ALS

  • MN Meriggioli
  • Continuum : Lifelong Learning in Neurology
  • 2009

A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis

  • DB Sanders, IK Hart, R Mantegazza
  • Neurology
  • 2008

Similar Papers

Loading similar papers…